Individualized chemotherapy for elderly patients with nonsmall cell lung cancer

Current Opinion in Oncology

Volumn 14, Issue 2, 2002, Pages 199-203

  Gridelli, Cesare ^a   Maione, Paolo ^a   Barletta, Emiddio ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

AGED; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; ELDERLY CARE; HUMAN; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; RISK FACTORS;

EID: 0036130447     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200203000-00010     Document Type: Review

References (47)

1. Global cancer statistics in the year 2000
2. Cancer statistics
3. Lung cancer in the elderly
4. The National Cancer Institute on Aging and the National Cancer Institute SEER. Collaborative study on comorbidity and early diagnosis of cancer in the elderly
5. Age trends of lung cancer stage at diagnosis. Implications for lung cancer screening in the elderly
6. Cancer patient survival in the elderly in Italy
7. Age and treatment of lung cancer
8. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study
9. Measuring comorbidity in older cancer patients
10. Perspective on comorbidities and cancer in older patients: Approaches to expand the knowledge base
11. Hemopoietic reserve in the older cancer patient: Clinical and economic considerations
12. Geriatric oncology: Challenge for the new century
13. Chemotherapy in the elderly: Pharmacologic considerations
14. Non-small cell lung cancer in very young and very old patients
15. Underrepresentation of patients 65 years of age or older in cancer-treatment trials
16. Chemotherapy in non small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
17. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non small cell lung cancer
18. Postoperative radiotherapy in non small cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomized controlled trials
19. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies
20. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC
21. Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis
22. Chemotherapy of advanced non small cell lung cancer in the elderly: An update
23. Treatment of elderly patients with non small cell lung cancer
24. Management of elderly patients with lung cancer
25. Weekly vinorelbine in elderly patients with non small cell lung cancer
26. Vinorelbine chemotherapy in non small cell lung cancer: Experience in elderly patients
27. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non small cell lung cancer. A two-stage phase II study
28. Vinorelbine treatment of advanced non small cell lung cancer with special emphasis on elderly patients
29. Vinorelbine in elderly patients with inoperable non small cell lung carcinoma
30. Effect of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer
31. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer
32. Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age
33. Gemcitabine in the treatment of non-small cell lung cancer for elderly patients
34. Gemcitabine monotherapy in elderly patients with advanced non small cell lung cancer. A multicenter phase II study
35. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non small cell lung cancer elderly patients: A phase II data from Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial
36. Gemcitabine as single agent in the treatment of elderly patients with advanced non-small cell lung cancer
37. Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age
38. Weekly docetaxel in the treatment of elderly patients with advanced non small cell lung carcinoma
39. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ function
40. Lung cancer: Small cell and non-small cell
41. Serious myelotoxicity of a carboplatin-etoposide regimen for advanced non small cell lung cancer
42. Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer
43. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study
44. Gemcitabine plus vinorelbine in non small cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin
45. Gemcitabine plus vinorelbine in elderly or unfit patients with non small cell lung cancer
46. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer
47. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase III trial: Gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients